Neurological and cognitive alterations induced by MDMA in humans
This preprint review (2021) surveys the literature on cognition and neuroimaging studies that have investigated functional and structural changes associated with MDMA use. It concludes that the neurocognitive/neurophysiological changes that occur with repeated MDMA use are potentially reversible over time.
Authors
- Montgomery, C.
- Roberts, C. A.
Published
Abstract
3,4 Methylenedioxymethamphetamine generally referred to as MDMA or ‘ecstasy’ is a ring-substituted phenethylamine stimulant which produces powerful empathogenic effects. Use of MDMA remains popular despite prohibition, and potential long-term negative consequences of repeated use. MDMA produces its acute subjective effects primarily by stimulating the release of serotonin via action at the serotonin transporter (SERT). There is evidence that MDMA administration may lead to long lasting neurotoxic effects on serotonin neurons in primates, and reductions in markers of central serotonin axons, and axon terminals in animals. In humans, demonstration of serotonergic neurotoxicity is much more difficult to identify, and much of the research is complicated by confounding issues of polysubstance use, genetic and environmental factors and reliance on self-reports of previous drug use. We do not review the mechanisms for neurotoxicity in detail as they are covered elsewhere in this special issue. There is a large body of literature, however, which has investigated potential cognitive and neurocognitive consequences of repeated MDMA use. Here we review the literature on cognition, and neuroimaging studies that have investigated structural and functional brain changes associated with ecstasy use.
Research Summary of 'Neurological and cognitive alterations induced by MDMA in humans'
Introduction
Montgomery and colleagues frame MDMA (3,4‑methylenedioxymethamphetamine, commonly ‘ecstasy’) as an empathogenic phenethylamine stimulant with widespread recreational use since the 1980s and continuing prevalence internationally. The introduction summarises its pharmacology—oral use with peak plasma concentrations around 1.5–3.0 hours and acute stimulation of serotonin, dopamine and norepinephrine via transporter action—and notes longstanding concerns that repeated use might damage the serotonin system and produce lasting neurocognitive consequences. The authors also note how demonstrations of serotonergic neurotoxicity in humans are complicated by polydrug use, genetic and environmental variability, and reliance on self‑report. The paper sets out to review the human literature on cognitive performance and neuroimaging evidence for structural and functional brain changes associated with recreational MDMA/ecstasy use. Rather than re‑reviewing cellular mechanisms of toxicity (covered elsewhere in the special issue), the review focuses on human neuroimaging modalities (MRI, fNIRS, EEG, SPECT, PET), acute laboratory administration studies, animal findings as context, and behavioural studies of long‑term users, with an emphasis on where findings converge or remain uncertain.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Study Details
- Study Typemeta
- Journal
- Compound
- Topics
- APA Citation
Montgomery, C., & Roberts, C. A. (2022). Neurological and cognitive alterations induced by MDMA in humans. Experimental Neurology, 347, 113888. https://doi.org/10.1016/j.expneurol.2021.113888
References (11)
Papers cited by this study that are also in Blossom
de la Torre, R., Farré, M., Roset, P. N. et al. · Annals of the New York Academy of Sciences (2006)
Doss, M. K., Weafer, J. J., Gallo, D. A. et al. · Neuropsychopharmacology (2017)
Greer, G. R. · Journal of Psychoactive Drugs (1986)
Halpern, J. H., Sherwood, A. R., Hudson, J. I. et al. · Addiction (2011)
Hasler, F., Ludewig, S. · Journal of Psychopharmacology (2008)
Kuypers, K. P. C., Ramaekers, J. G. · Psychopharmacology (2006)
Kuypers, K. P. C., Ramaekers, J. G. · Journal of Psychopharmacology (2005)
Liechti, M. E., Gamma, A., Vollenweider, F. X. · Psychopharmacology (2001)
Roberts, C. A., Jones, A., Montgomery, C. · Psychological Medicine (2016)
Simmler, L. D., Hysek, C. M., Liechti, M. E. · Journal of Clinical Endocrinology Metabolism (2011)
Show all 11 referencesShow fewer
Yazar-Klosinski, B., Mithoefer, M. C. · Clinical Pharmacology and Therapeutics (2016)
Cited By (3)
Papers in Blossom that reference this study
Ramaekers, J. G., Kuypers, K. P. C., Vollenweider, F. X. · Molecular Psychiatry (2026)
Zacher, A., Zimmermann, J., Cole, D. M. et al. · European Neuropsychopharmacology (2024)
Ponomarenko, P., Seragnoli, F., Calder, A. et al. · Journal of Psychopharmacology (2023)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.